 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | universal chimeric antigen receptor-modified AT19 cells / Wuhan Union Hospital, Chengdu USino Techno
New P1 trial: Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies (clinicaltrials.gov) - Mar 15, 2021
P1, N=27, Recruiting, Sponsor: Wuhan Union Hospital, China